Below are the most recent publications written about "Hodgkin Disease" by people in Profiles.
-
Arter ZL, Meghpara S, Mignano S, Berenberg J. A Rare Coexistence of Seminoma and Hodgkin's Lymphoma in Hawai'i. Hawaii J Health Soc Welf. 2021 12; 80(12):295-297.
-
Davidow K, Bunin N, Goldfarb S, Li Y, Freedman JL. Pulmonary Outcomes After Autologous Stem Cell Transplant for Hodgkin Lymphoma. J Pediatr Hematol Oncol. 2022 08 01; 44(6):e926-e929.
-
Metzger ML, Link MP, Billett AL, Flerlage J, Lucas JT, Mandrell BN, Ehrhardt MJ, Bhakta N, Yock TI, Friedmann AM, de Alarcon P, Luna-Fineman S, Larsen E, Kaste SC, Shulkin B, Lu Z, Li C, Hiniker SM, Donaldson SS, Hudson MM, Krasin MJ. Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation. J Clin Oncol. 2021 07 10; 39(20):2276-2283.
-
Harer K, Mann J, Muhlbauer N, Welch J, Alverson B. A Case Report of Pediatric Paraneoplastic Dysautonomia. Pediatr Emerg Care. 2020 Dec; 36(12):e742-e744.
-
Nagpal P, Descalzi-Montoya DB, Lodhi N. The circuitry of the tumor microenvironment in adult and pediatric Hodgkin lymphoma: cellular composition, cytokine profile, EBV, and exosomes. Cancer Rep (Hoboken). 2021 04; 4(2):e1311.
-
Mostyka M, Birch MM, Samstein B, Pittman ME. Hidden Carcinoma: Pitfalls in the Diagnosis of Lymphoepithelioma-Like Cholangiocarcinoma. Int J Surg Pathol. 2020 Dec; 28(8):872-878.
-
Damlaj M, Abuelgasim KA, Alhejazi A, Alahmari B, Alaskar A, Alzahrani M. Brentuximab vedotin containing salvage followed by consolidation post autologous hematopoietic stem cell transplantation in high risk relapsed refractory classical Hodgkin lymphoma. Bone Marrow Transplant. 2020 12; 55(12):2322-2325.
-
Gittens AT, Clarke JD, Abdelbaki S, Kwon JS. A 72-Year-Old Man With a Violaceous Rash?and Sepsis. Chest. 2020 02; 157(2):e41-e45.
-
Cohen JB, Wei L, Maddocks KJ, Christian B, Heffner LT, Langston AA, Lechowicz MJ, Porcu P, Flowers CR, Devine SM, Blum KA. Gemcitabine and bendamustine is a safe and effective salvage regimen for patients with recurrent/refractory Hodgkin lymphoma: Results of a phase 1/2 study. Cancer. 2020 03 15; 126(6):1235-1242.
-
Abuelgasim KA, Alzahrani M, Alsharhan Y, Khairi M, Hommady M, Gmati G, Salama H, Ali O, Alahmari B, Masuadi EM, Alaskar A, Alhejazi A, Damlaj M. Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma. Bone Marrow Transplant. 2019 07; 54(7):1168-1172.